ALKS 4230

BIOLOGICAL2 trials

Sponsors

Mural Oncology, Inc

Conditions

Advanced Solid Tumors

Phase 1

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

CompletedNCT02799095

Mural Oncology, IncAdvanced Solid Tumors

Start: 2016-09-14End: 2023-08-02Updated: 2025-05-21

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

CompletedNCT03861793

Mural Oncology, IncAdvanced Solid Tumors

Start: 2019-02-26End: 2023-03-01Updated: 2024-03-05

Related Papers

Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial

Journal for ImmunoTherapy of Cancer2025-08-012 citations

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

Journal for ImmunoTherapy of Cancer2024-11-0121 citations

Abstract A099: Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab

Cancer Research2024-03-04

724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)

Regular and Young Investigator Award Abstracts2023-10-31

740 Pattern of natural killer (NK) cell (CD16<sup>+</sup>CD56<sup>+</sup>) expansion correlates with response outcomes with nemvaleukin alfa treatment

Regular and Young Investigator Award Abstracts2023-10-31

Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.

Journal of Clinical Oncology2022-06-0137 citations

Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.

Journal of Clinical Oncology2022-02-163 citations

Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.

Journal of Clinical Oncology2022-01-191 citations

Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.

Journal of Clinical Oncology2021-05-2012 citations

ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2021-05-2010 citations

347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

Regular and Young Investigator Award Abstracts2020-11-014 citations

373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

Regular and Young Investigator Award Abstracts2020-11-01

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-203 citations

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-205 citations